
    
      Adjuvant therapy has been proved effective in treating stage II-IIIA non-small-cell lung
      cancer. However, few data on the treating time of adjuvant therapy is available. Here we
      conduct a randomized, prospective study to compare the recurrence-free survival after 1-year
      or 2-year treatment with icotinib in EGFR-mutated non-small cell lung cancer patients.
    
  